Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ethinylestradiol/levonorgestrel transdermal - Agile Therapeutics

Drug Profile

Ethinylestradiol/levonorgestrel transdermal - Agile Therapeutics

Alternative Names: AG 200 ER; AG 200 ER (SmP); AG 200 SP; AG-200-15; Ethinyl estradiol and levonorgestrel transdermal system; Low dose EE/LNG; Twirla

Latest Information Update: 13 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agile Therapeutics
  • Class Alkylated estrogenic steroids; Contraceptives; Hormonal replacements; Norpregnanes; Norpregnatrienes; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Pregnancy

Most Recent Events

  • 12 Feb 2019 The comparative wear study meets its primary endpoint of non-inferiority
  • 12 Feb 2019 Topline efficacy results from a comparative wear study released by Agile Therapeutics
  • 10 Jan 2019 Agile Therapeutics announces intention to re-submit NDA to US FDA in the first half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top